Current understanding of the molecular mechanisms of circulating permeability factor in focal segmental glomerulosclerosis

The pathogenetic mechanisms underlying the onset and the post-transplant recurrence of primary focal segmental glomerulosclerosis (FSGS) are complex and remain yet to be fully elucidated. However, a growing body of evidence emphasizes the pivotal role of the immune system in both initiating and perpetuating the disease. Extensive investigations, encompassing both experimental models and patient studies, have implicated T cells, B cells, and complement as crucial actors in the pathogenesis of primary FSGS, with various molecules being proposed as potential “circulating factors” contributing to the disease and its recurrence post kidney-transplantation. In this review, we critically assessed the existing literature to identify essential pathways for a comprehensive characterization of the pathogenesis of FSGS. Recent discoveries have shed further light on the intricate interplay between these mechanisms. We present an overview of the current understanding of the engagement of distinct molecules and immune cells in FSGS pathogenesis while highlighting critical knowledge gaps that require attention. A thorough characterization of these intricate immune mechanisms holds the potential to identify noninvasive biomarkers that can accurately identify patients at high risk of post-transplant recurrence. Such knowledge can pave the way for the development of targeted and personalized therapeutic approaches in the management of FSGS.

[1]  G. Remuzzi,et al.  Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome , 2023, International journal of molecular sciences.

[2]  M. Saleem,et al.  What is circulating factor disease and how is it currently explained? , 2023, Pediatric Nephrology.

[3]  D. Altshuler,et al.  Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. , 2023, The New England journal of medicine.

[4]  C. Thongprayoon,et al.  Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: a Systematic review , 2023, Renal failure.

[5]  C. Srichomthong,et al.  Pathogenic variant detection rate by whole exome sequencing in Thai patients with biopsy-proven focal segmental glomerulosclerosis , 2023, Scientific Reports.

[6]  L. M. dos Reis,et al.  Urinary CD80 and Serum suPAR as Biomarkers of Glomerular Disease among Adults in Brazil , 2023, Diagnostics.

[7]  S. Sanjad,et al.  Current Understanding of Nephrotic Syndrome in Children. , 2022, Pediatric clinics of North America.

[8]  P. Heeger,et al.  Cutting Edge: Neutrophil Complement Receptor Signaling Is Required for BAFF-Dependent Humoral Responses in Mice. , 2022, Journal of immunology.

[9]  G. Tobón,et al.  B-cell activating factor (BAFF) and its receptors’ expression in pediatric nephrotic syndrome is associated with worse prognosis , 2022, PloS one.

[10]  G. La Manna,et al.  Decay-Accelerating Factor Expression Modulates the Severity of Experimental Focal Segmental Glomerulosclerosis , 2022, Kidney360.

[11]  A. Sidhom ATYPICAL IPEX SYNDROME PRESENTING AS SEVERE APLASTIC ANEMIA AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS RESPONSIVE TO TACROLIMUS , 2022, Annals of Allergy, Asthma & Immunology.

[12]  J. Lieske,et al.  Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis. , 2022, Kidney international.

[13]  M. Indeykina,et al.  Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease , 2022, International journal of molecular sciences.

[14]  J. Deegens,et al.  Novel mouse strains to study circulating permeability factor(s) in primary focal segmental glomerulosclerosis , 2022, PLoS ONE.

[15]  A. Liew,et al.  How I Treat Focal Segmental Glomerulosclerosis , 2022, Clinical journal of the American Society of Nephrology : CJASN.

[16]  M. Sambharia,et al.  Monogenic focal segmental glomerulosclerosis: A conceptual framework for identification and management of a heterogeneous disease , 2022, American journal of medical genetics. Part C, Seminars in medical genetics.

[17]  Wen-Jing Zhao,et al.  Transition from minimal change disease to focal segmental glomerulosclerosis related to occupational exposure: A case report , 2022, World journal of clinical cases.

[18]  H. Alhozali,et al.  Histopathological and Clinical Findings of Biopsy-Proven Focal and Segmental Glomerulosclerosis: A Retrospective Study , 2022, Cureus.

[19]  A. Sinha,et al.  Interventions for focal segmental glomerulosclerosis in adults. , 2022, The Cochrane database of systematic reviews.

[20]  K. Huang,et al.  CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma , 2022, Frontiers in Immunology.

[21]  A. Bonnefoy,et al.  Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis , 2022, Kidney international reports.

[22]  M. Vivarelli,et al.  B-Cell Dysregulation in Idiopathic Nephrotic Syndrome: What We Know and What We Need to Discover , 2022, Frontiers in Immunology.

[23]  I. Shaheen,et al.  Management of recurrent focal segmental glomerulosclerosis (FSGS) post renal transplantation. , 2021, Transplantation reviews.

[24]  K. Campbell,et al.  Urine single cell RNA-sequencing in FSGS – hope for the future. , 2021, Kidney International Reports.

[25]  N. Chebotareva,et al.  Serum levels of plasminogen activator urokinase receptor and cardiotrophin-like cytokine factor 1 in patients with nephrotic syndrome. , 2021, Clinical nephrology.

[26]  S. Waikar,et al.  Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology , 2021, Journal of the American Society of Nephrology : JASN.

[27]  J. Wetzels,et al.  Human pluripotent stem cell-derived kidney organoids for personalized congenital and idiopathic nephrotic syndrome modeling , 2021, bioRxiv.

[28]  B. Rovin,et al.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[29]  B. Rovin,et al.  Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[30]  Jianhua Mao,et al.  Seven novel podocyte autoantibodies were identified to diagnosis a new disease subgroup-autoimmune Podocytopathies. , 2021, Clinical immunology.

[31]  G. Ghiggeri,et al.  CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome , 2021, Frontiers in Immunology.

[32]  M. Prunotto,et al.  Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial , 2021, Journal of the American Society of Nephrology : JASN.

[33]  B. Rovin,et al.  Natural Antibody and Complement Activation Characterize Patients with Idiopathic Nephrotic Syndrome. , 2021, American journal of physiology. Renal physiology.

[34]  F. Emma,et al.  Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study , 2021, Pediatric Nephrology.

[35]  N. Iwasaki,et al.  Cardiotrophin like cytokine factor 1 (CLCF1) alleviates bone loss in osteoporosis mouse models by suppressing osteoclast differentiation through activating interferon signaling and repressing the nuclear factor-κB signaling pathway. , 2021, Bone.

[36]  A. Moktefi,et al.  CMIP interacts with WT1 and targets it on the proteasome degradation pathway , 2021, Clinical and translational medicine.

[37]  A. Pukajło-Marczyk,et al.  Involvement of Hemopexin in the Pathogenesis of Proteinuria in Children with Idiopathic Nephrotic Syndrome , 2021, Journal of clinical medicine.

[38]  A. Bouts,et al.  Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-analysis , 2021, Pediatrics.

[39]  M. Hogan,et al.  Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. , 2021, Mayo Clinic proceedings.

[40]  J. Wetzels,et al.  Therapeutic trials in adult FSGS: lessons learned and the road forward , 2021, Nature Reviews Nephrology.

[41]  B. Knebelman,et al.  Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys , 2021, Kidney international reports.

[42]  N. Carlozzi,et al.  Health-Related Quality of Life in Focal Segmental Glomerular Sclerosis and Minimal Change Disease: A Qualitative Study of Children and Adults to Inform Patient-Reported Outcomes , 2021, Kidney medicine.

[43]  Y. Chan,et al.  Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy. , 2021, Translational research : the journal of laboratory and clinical medicine.

[44]  Jingwen Huang,et al.  Association of cardiotrophin-like cytokine factor 1 levels in peripheral blood mononuclear cells with bone mineral density and osteoporosis in postmenopausal women , 2021, BMC Musculoskeletal Disorders.

[45]  Qiang Sun,et al.  Decreased Circulating Transitional B-Cell to Memory B-Cell Ratio Is a Risk Factor for Relapse in Children with Steroid-Sensitive Nephrotic Syndrome , 2020, Nephron.

[46]  R. Nee,et al.  Focal Segmental Glomerulosclerosis, Risk Factors for End Stage Kidney Disease, and Response to Immunosuppression. , 2020, Kidney360.

[47]  E. Audureau,et al.  Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  S. Kalkhof,et al.  Novel diagnostic and therapeutic techniques reveal changed metabolic profiles in recurrent focal segmental glomerulosclerosis , 2020, Scientific Reports.

[49]  C. Ponticelli,et al.  Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association , 2020, Frontiers in Medicine.

[50]  L. Gesualdo,et al.  High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[51]  T. Meitinger,et al.  Identification of disease-causing variants by comprehensive genetic testing with exome sequencing in adults with suspicion of hereditary FSGS , 2020, European Journal of Human Genetics.

[52]  G. Remuzzi,et al.  Podocytopathies , 2020, Nature Reviews Disease Primers.

[53]  A. Levin,et al.  Alport Syndrome Classification and Management , 2020, Kidney medicine.

[54]  G. Fernández-Juárez,et al.  Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective , 2020, Nephron.

[55]  H. Trimarchi Focal Segmental Glomerulosclerosis and Scheduled Pretransplant Plasmapheresis: A Timely Diagnosis of Nail-Patella Syndrome Avoided More Futile Immunosuppression , 2020, Case reports in nephrology.

[56]  D. Friedman,et al.  APOL1 Nephropathy: From Genetics to Clinical Applications. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[57]  Shigeru Tanaka,et al.  Utility of Columbia classification in focal segmental glomerulosclerosis: renal prognosis and treatment response among the pathological variants. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[58]  Ming-hui Zhao,et al.  Complement activation profile of patients with primary focal segmental glomerulosclerosis , 2020, PloS one.

[59]  A. Bomback,et al.  Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[60]  C. Thongprayoon,et al.  Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis , 2020, BMC Nephrology.

[61]  B. Kasiske,et al.  KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. , 2020, Transplantation.

[62]  G. M. Neto,et al.  Recurrence of FSGS after Kidney Transplantation in Adults. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[63]  K. Nakanishi,et al.  Comprehensive genetic diagnosis of Japanese patients with severe proteinuria , 2020, Scientific Reports.

[64]  H. Lorenzo,et al.  Idiopathic nephrotic syndrome and serum permeability factors: a molecular jigsaw puzzle , 2019, Cell and Tissue Research.

[65]  M. Saleem Molecular stratification of idiopathic nephrotic syndrome , 2019, Nature Reviews Nephrology.

[66]  Qiang Sun,et al.  Altered B-Lymphocyte Homeostasis in Idiopathic Nephrotic Syndrome , 2019, Front. Pediatr..

[67]  V. Nair,et al.  Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis , 2019, PloS one.

[68]  M. Rastaldi,et al.  Atypical IgM on T cells predict relapse and steroid dependence in idiopathic nephrotic syndrome. , 2019, Kidney international.

[69]  M. Saleem,et al.  Human Th17 cells produce a soluble mediator that increases podocyte motility via signalling pathways which mimic PAR-1 activation. , 2019, American journal of physiology. Renal physiology.

[70]  D. Geary,et al.  Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Proteomics , 2019, Kidney international reports.

[71]  Wasim Hussain,et al.  Follicular B2 Cell Activation and Class Switch Recombination Depend on Autocrine C3ar1/C5ar1 Signaling in B2 Cells , 2019, The Journal of Immunology.

[72]  R. B. Henderson,et al.  Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[73]  Thomas M. Kitzler,et al.  Intrinsic tumor necrosis factor-α pathway is activated in a subset of patients with focal segmental glomerulosclerosis , 2019, PloS one.

[74]  E. Rocha-Vieira,et al.  Pediatric Patients With Steroid-Sensitive Nephrotic Syndrome Have Higher Expression of T Regulatory Lymphocytes in Comparison to Steroid-Resistant Disease , 2019, Front. Pediatr..

[75]  S. Rieder,et al.  Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. , 2019, Advanced drug delivery reviews.

[76]  A. Paterson,et al.  Integration of Genetic Testing and Pathology for the Diagnosis of Adults with FSGS. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[77]  J. Reiser,et al.  Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab , 2018, BMC Nephrology.

[78]  A. Bagga,et al.  Management of steroid-resistant nephrotic syndrome in children and adolescents. , 2018, The Lancet. Child & adolescent health.

[79]  O. Gribouval,et al.  Identification of genetic causes for sporadic steroid-resistant nephrotic syndrome in adults. , 2018, Kidney international.

[80]  G. Gambaro,et al.  DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. , 2018, Journal of the American Society of Nephrology : JASN.

[81]  F. Emma,et al.  B cell phenotype in pediatric idiopathic nephrotic syndrome , 2018, Pediatric Nephrology.

[82]  M. Rudnicki,et al.  Successful management of recurrent focal segmental glomerulosclerosis , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[83]  R. Parekh,et al.  Idiopathic nephrotic syndrome in children , 2018, The Lancet.

[84]  R. B. Henderson,et al.  Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial , 2018, The Lancet.

[85]  E. Daugas,et al.  Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice. , 2018, Journal of autoimmunity.

[86]  S. Funk,et al.  Alport syndrome and Pierson syndrome: Diseases of the glomerular basement membrane. , 2018, Matrix biology : journal of the International Society for Matrix Biology.

[87]  C. Alpers,et al.  AJKD Atlas of Renal Pathology: Pierson Syndrome. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[88]  K. Nath,et al.  Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. , 2018, Journal of the American Society of Nephrology : JASN.

[89]  G. Fernández-Juárez,et al.  Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults , 2018, Clinical kidney journal.

[90]  P. O'kelly,et al.  Renal transplant outcomes in primary FSGS compared with other recipients and risk factors for recurrence: A national review of the Irish Transplant Registry , 2018, Clinical transplantation.

[91]  R. Lennon,et al.  Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how? , 2017, Pediatric Nephrology.

[92]  G. Camussi,et al.  Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS , 2017, PloS one.

[93]  M. Saleem,et al.  Deriving and understanding the risk of post-transplant recurrence of nephrotic syndrome in the light of current molecular and genetic advances , 2017, Pediatric Nephrology.

[94]  D. Youssef,et al.  Tumor necrosis factor alpha gene polymorphisms and haplotypes in Egyptian children with nephrotic syndrome , 2017, Cytokine.

[95]  Chris Buxton,et al.  Clinical genetic testing using a custom-designed steroid-resistant nephrotic syndrome gene panel: analysis and recommendations , 2017, Journal of Medical Genetics.

[96]  S. Beaudreuil,et al.  Optimal management of primary focal segmental glomerulosclerosis in adults , 2017, International journal of nephrology and renovascular disease.

[97]  Joseph H. Marcus,et al.  Overexpression of the Cytokine BAFF and Autoimmunity Risk , 2017, The New England journal of medicine.

[98]  M. Lanaspa,et al.  Angiopoietin-like-4 and minimal change disease , 2017, PloS one.

[99]  W. Dixon,et al.  Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community , 2017, BMJ Open.

[100]  J. Yazdany,et al.  Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. , 2017, Autoimmunity reviews.

[101]  F. Emma,et al.  Minimal Change Disease. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[102]  F. Cosio,et al.  Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. , 2017, Kidney international.

[103]  M. Stangou,et al.  Impact of Τh1 and Τh2 cytokines in the progression of idiopathic nephrotic syndrome due to focal segmental glomerulosclerosis and minimal change disease , 2016, Journal of nephropathology.

[104]  D. Scadden,et al.  Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease , 2016, Nature Medicine.

[105]  B. Smeets,et al.  Minimal change disease and idiopathic FSGS: manifestations of the same disease , 2016, Nature Reviews Nephrology.

[106]  A. Więcek,et al.  Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report. , 2016, Transplantation proceedings.

[107]  Ming-hui Zhao,et al.  Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[108]  M. Saleem,et al.  Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View , 2016, Journal of immunology research.

[109]  Richard J. Johnson,et al.  Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms , 2016, Pediatric Nephrology.

[110]  G. Remuzzi,et al.  A previously unrecognized role of C3a in proteinuric progressive nephropathy , 2016, Scientific Reports.

[111]  L. Ravà,et al.  B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. , 2016, Journal of the American Society of Nephrology : JASN.

[112]  L. Laurin,et al.  Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[113]  I. Barlan,et al.  The effect of systemic corticosteroids on the innate and adaptive immune system in children with steroid responsive nephrotic syndrome , 2016, European Journal of Pediatrics.

[114]  Geetha Chalasani,et al.  B Cells, Antibodies, and More. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[115]  T. Slowinski,et al.  Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor–Mediated Podocyte &bgr;3-integrin Activation , 2015, Transplantation.

[116]  G. Vlachopanos,et al.  Plasma Exchange for the Recurrence of Primary Focal Segmental Glomerulosclerosis in Adult Renal Transplant Recipients: A Meta-Analysis , 2015, Journal of transplantation.

[117]  T. Srivastava,et al.  Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. , 2015, Translational research : the journal of laboratory and clinical medicine.

[118]  D. Gipson,et al.  Complement Activation in Patients with Focal Segmental Glomerulosclerosis , 2015, PloS one.

[119]  T. Srivastava,et al.  Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group , 2015, BMC Nephrology.

[120]  T. Srivastava,et al.  Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family , 2015, Journal of immunology research.

[121]  J. Davin The glomerular permeability factors in idiopathic nephrotic syndrome , 2015, Pediatric Nephrology.

[122]  A. Anarat,et al.  Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[123]  H. Cheong,et al.  Familial IPEX syndrome: Different glomerulopathy in two siblings , 2015, Pediatrics international : official journal of the Japan Pediatric Society.

[124]  A. C. Simões e Silva,et al.  The experimental model of nephrotic syndrome induced by Doxorubicin in rodents: an update , 2015, Inflammation Research.

[125]  A. Fogo Causes and pathogenesis of focal segmental glomerulosclerosis , 2015, Nature Reviews Nephrology.

[126]  J. Deegens,et al.  Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[127]  V. Jha,et al.  Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[128]  M. Sarwal,et al.  A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation , 2014, Science Translational Medicine.

[129]  M. Kretzler,et al.  A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease , 2014, Kidney international.

[130]  V. D’Agati,et al.  Morphologic variants of focal segmental glomerulosclerosis and their significance. , 2014, Advances in chronic kidney disease.

[131]  J. Radhakrishnan,et al.  The treatment of idiopathic focal segmental glomerulosclerosis in adults. , 2014, Advances in chronic kidney disease.

[132]  I. Pastan,et al.  Mice are unable to endogenously regenerate podocytes during the repair of immunotoxin-induced glomerular injury. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[133]  M. Rudnicki,et al.  Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. , 2014, Journal of the American Society of Nephrology : JASN.

[134]  D. Cattran,et al.  Glomerular diseases: FSGS. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[135]  R. Pandey,et al.  Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. , 2014, Kidney international.

[136]  M. Nangaku,et al.  A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. , 2014, Kidney international.

[137]  J. Deegens,et al.  The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. , 2014, Kidney international.

[138]  S. Kersten,et al.  Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome , 2013, Nature Medicine.

[139]  H. Trachtman,et al.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[140]  C. Langman,et al.  Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[141]  A. Moudgil,et al.  Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome , 2013, Pediatric Nephrology.

[142]  J. Deegens,et al.  Serum suPAR in patients with FSGS: trash or treasure? , 2013, Pediatric Nephrology.

[143]  V. D’Agati,et al.  Association of histologic variants in FSGS clinical trial with presenting features and outcomes. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[144]  J. Thurman,et al.  IgM contributes to glomerular injury in FSGS. , 2013, Journal of the American Society of Nephrology : JASN.

[145]  G. Remuzzi,et al.  Recent Progress in the Pathophysiology and Treatment of FSGS Recurrence , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[146]  J. Pers,et al.  The complexity of the BAFF TNF-family members: implications for autoimmunity. , 2012, Journal of autoimmunity.

[147]  Richard J. H. Smith,et al.  Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement factor H and C3. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[148]  J. Pers,et al.  B-lymphocytes govern the pathogenesis of Sjögren's syndrome. , 2012, Current pharmaceutical biotechnology.

[149]  A. Fornoni,et al.  Podocyte Foot Process Effacement in Postreperfusion Allograft Biopsies Correlates With Early Recurrence of Proteinuria in Focal Segmental Glomerulosclerosis , 2012, Transplantation.

[150]  L. Rostaing,et al.  Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[151]  J. Leventhal,et al.  Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. , 2012, The New England journal of medicine.

[152]  S. Chugh,et al.  New insights into human minimal change disease: lessons from animal models. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[153]  V. D’Agati,et al.  Clinical trial of focal segmental glomerulosclerosis in children and young adults. , 2011, Kidney international.

[154]  E. Salido,et al.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis , 2011, Nature Medicine.

[155]  M. Kopač,et al.  Partial Remission of Resistant Nephrotic Syndrome After Oral Galactose Therapy , 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[156]  M. Rastaldi,et al.  Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis , 2011, Science Translational Medicine.

[157]  Xia Li,et al.  Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. , 2011, Clinical immunology.

[158]  B. Tazón-Vega,et al.  Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[159]  T. Greene,et al.  Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. , 2011, Kidney international.

[160]  K. Pfeiffer,et al.  Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. , 2011, Journal of the American Society of Nephrology : JASN.

[161]  D. Harris,et al.  Adriamycin nephropathy: A model of focal segmental glomerulosclerosis , 2011, Nephrology.

[162]  V. Savin,et al.  Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[163]  S. Kersten,et al.  Podocyte secreted Angiopoietin-like 4 mediates proteinuria in glucocorticoid sensitive nephrotic syndrome , 2010, Nature Medicine.

[164]  Juan I. Young,et al.  Podocyte-Specific Overexpression of Wild Type or Mutant Trpc6 in Mice Is Sufficient to Cause Glomerular Disease , 2010, PloS one.

[165]  K. Dahan,et al.  c-mip Impairs Podocyte Proximal Signaling and Induces Heavy Proteinuria , 2010, Science Signaling.

[166]  R. Salomon,et al.  Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[167]  Jesper Eugen-Olsen,et al.  suPAR: The Molecular Crystal Ball , 2009, Disease markers.

[168]  M. Dallman,et al.  Podocin inactivation in mature kidneys causes focal segmental glomerulosclerosis and nephrotic syndrome. , 2009, Journal of the American Society of Nephrology : JASN.

[169]  C. Déziel,et al.  FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[170]  N. Printza,et al.  Peripheral CD19+ B cells are increased in children with active steroid-sensitive nephrotic syndrome , 2009, NDT plus.

[171]  M. Atkinson,et al.  T regulatory cell function in idiopathic minimal lesion nephrotic syndrome , 2009, Pediatric Nephrology.

[172]  S. Hillion,et al.  Transmembrane BAFF from rheumatoid synoviocytes requires interleukin-6 to induce the expression of recombination-activating gene in B lymphocytes. , 2009, Arthritis and rheumatism.

[173]  M. Cancro,et al.  The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. , 2009, The Journal of clinical investigation.

[174]  C. Alpers,et al.  Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells. , 2009, The Journal of clinical investigation.

[175]  S. Leroy,et al.  Successful Anti‐TNFα Treatment in a Child with Posttransplant Recurrent Focal Segmental Glomerulosclerosis , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[176]  S. Shankland,et al.  Inducible rodent models of acquired podocyte diseases. , 2009, American journal of physiology. Renal physiology.

[177]  S. Satchell,et al.  Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. , 2008, Journal of the American Society of Nephrology : JASN.

[178]  Maristela L Onozato,et al.  Glomerular albumin filtration through podocyte cell body in puromycin aminonucleoside nephrotic rat , 2008, Medical Molecular Morphology.

[179]  V. Savin,et al.  Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. , 2008, Translational research : the journal of laboratory and clinical medicine.

[180]  V. Jha,et al.  Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[181]  C. Antignac,et al.  A missense mutation in podocin leads to early and severe renal disease in mice. , 2008, Kidney international.

[182]  V. D’Agati The spectrum of focal segmental glomerulosclerosis: new insights , 2008, Current opinion in nephrology and hypertension.

[183]  H. Kawachi,et al.  Nephrin mediates actin reorganization via phosphoinositide 3-kinase in podocytes. , 2008, Kidney international.

[184]  E. Haddad,et al.  A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. , 2007, Journal of the American Society of Nephrology : JASN.

[185]  P. Tan,et al.  Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. , 2007, Journal of the American Society of Nephrology : JASN.

[186]  F. Hildebrandt,et al.  Nephrotic Syndrome in the First Year of Life: Two Thirds of Cases Are Caused by Mutations in 4 Genes (NPHS1, NPHS2, WT1, and LAMB2) , 2007, Pediatrics.

[187]  S. Shankland,et al.  Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. , 2006, Kidney international.

[188]  V. D’Agati,et al.  Cellular focal segmental glomerulosclerosis: Clinical and pathologic features. , 2006, Kidney international.

[189]  P. Schneider,et al.  BAFF, APRIL and their receptors: structure, function and signaling. , 2006, Seminars in immunology.

[190]  L. Gesualdo,et al.  Posttransplant Recurrence of Proteinuria in a Case of Focal Segmental Glomerulosclerosis Associated with WT1 Mutation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[191]  A. E. El Nahas,et al.  Immunosuppressive Treatment of Idiopathic Focal Segmental Glomerulosclerosis: A Five-Year Follow-Up Study , 2006, Nephron Clinical Practice.

[192]  R J Falk,et al.  Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. , 2006, Kidney international.

[193]  B. Sampaio-Maia,et al.  Blunted renal dopaminergic system activity in puromycin aminonucleoside-induced nephrotic syndrome. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[194]  C. Usal,et al.  Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in Buffalo/Mna rats. , 2005, Kidney international.

[195]  L. Holzman,et al.  Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. , 2005, Journal of the American Society of Nephrology : JASN.

[196]  B. Tönshoff,et al.  Recurrence of Focal-Segmental Glomerulosclerosis in Children after Renal Transplantation: Clinical and Genetic Aspects , 2005, Transplantation.

[197]  J. Scholey,et al.  Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. , 2005, Journal of the American Society of Nephrology : JASN.

[198]  I. Pastan,et al.  Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. , 2005, Journal of the American Society of Nephrology : JASN.

[199]  D. Adu,et al.  Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion. , 2005, Kidney international.

[200]  N. Duncan,et al.  Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[201]  G. Appel,et al.  Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. , 2004, Clinical nephrology.

[202]  W. Couser,et al.  C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. , 2004, Kidney international.

[203]  G. Vlotides,et al.  Novel neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3)/cardiotrophin-like cytokine (CLC)--a novel gp130 cytokine with pleiotropic functions. , 2004, Cytokine & growth factor reviews.

[204]  D. Raveh,et al.  Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome , 2004, Pediatric Nephrology.

[205]  Agnes B Fogo,et al.  Pathologic classification of focal segmental glomerulosclerosis: a working proposal. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[206]  B. Smeets,et al.  Podocyte changes upon induction of albuminuria in Thy-1.1 transgenic mice. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[207]  K. Anderson,et al.  Functional significance of novel neurotrophin‐1/B cell‐stimulating factor‐3 (cardiotrophin‐like cytokine) for human myeloma cell growth and survival , 2003, British journal of haematology.

[208]  Y. Tay,et al.  Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. , 2003, Kidney international.

[209]  R. Oppenheim,et al.  Cardiotrophin-Like Cytokine/Cytokine-Like Factor 1 is an Essential Trophic Factor for Lumbar and Facial Motoneurons In Vivo , 2003, The Journal of Neuroscience.

[210]  R. Gerszten,et al.  Mice deficient in α-actinin-4 have severe glomerular disease , 2003 .

[211]  A. Berg,et al.  Production of hemopexin by TNF-α stimulated human mesangial cells , 2003 .

[212]  B. Vanderhyden,et al.  Focal and Segmental Glomerulosclerosis in Mice with Podocyte-Specific Expression of Mutant α-Actinin-4 , 2003 .

[213]  V. D’Agati,et al.  Pathologic classification of focal segmental glomerulosclerosis. , 2003, Seminars in nephrology.

[214]  M. Pollak The genetic basis of FSGS and steroid-resistant nephrosis. , 2003, Seminars in nephrology.

[215]  P. Eggers,et al.  Trends in the epidemiology of focal segmental glomerulosclerosis. , 2003, Seminars in nephrology.

[216]  B. Nardelli,et al.  G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS , 2003, The Journal of experimental medicine.

[217]  J. Wetzels,et al.  Antibody-induced albuminuria and accelerated focal glomerulosclerosis in the Thy-1.1 transgenic mouse. , 2002, Kidney international.

[218]  W. Wurst,et al.  Nephrin TRAP mice lack slit diaphragms and show fibrotic glomeruli and cystic tubular lesions. , 2002, Journal of the American Society of Nephrology : JASN.

[219]  R. Faggioni,et al.  Regulatory Effects of Novel Neurotrophin-1/B Cell-Stimulating Factor-3 (Cardiotrophin-Like Cytokine) on B Cell Function , 2002, The Journal of Immunology.

[220]  R. Cunard,et al.  T cells and minimal change disease. , 2002, Journal of the American Society of Nephrology : JASN.

[221]  F. Altruda,et al.  Hemopexin: structure, function, and regulation. , 2002, DNA and cell biology.

[222]  D. Kerjaschki,et al.  Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats. , 2002, The Journal of clinical investigation.

[223]  D. Kerjaschki,et al.  The Buffalo/Mna rat, an animal model of FSGS recurrence after renal transplantation. , 2001, Transplantation proceedings.

[224]  Y. H. Kim,et al.  Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. , 2001, Kidney international.

[225]  T. Graf,et al.  Anuria, Omphalocele, and Perinatal Lethality in Mice Lacking the Cd34-Related Protein Podocalyxin , 2001, The Journal of experimental medicine.

[226]  Y. Wang,et al.  Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. , 2000, Kidney international.

[227]  M. Herrmann,et al.  Dominant T cells in idiopathic nephrotic syndrome of childhood. , 2000, Kidney international.

[228]  J. Baller,et al.  Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. , 2000, Kidney international.

[229]  L. Hebert,et al.  A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. , 1999, Kidney international.

[230]  Michael Loran Dustin,et al.  Congenital nephrotic syndrome in mice lacking CD2-associated protein. , 1999, Science.

[231]  T. Boone,et al.  Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[232]  S. Ruben,et al.  Computational EST database analysis identifies a novel member of the neuropoietic cytokine family. , 1999, Biochemical and biophysical research communications.

[233]  S. Adler,et al.  Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[234]  D. Cattran,et al.  Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[235]  G. Nyberg,et al.  Focal segmental glomerulosclerosis in a kidney transplant population: hereditary and sporadic forms , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[236]  S. Swan,et al.  Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. , 1996, The New England journal of medicine.

[237]  K. Furusho,et al.  Involvement of interleukin (IL)‐13, but not IL‐4, in spontaneous IgE and IgG4 production in nephrotic syndrome , 1995, European journal of immunology.

[238]  M. Schwartz,et al.  Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[239]  E. Lewis,et al.  Primary focal segmental glomerulosclerosis: clinical course and response to therapy. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[240]  V. Savin,et al.  Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[241]  A. Edefonti,et al.  A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome , 1993, Pediatric Nephrology.

[242]  A. Koyama,et al.  A glomerular permeability factor produced by human T cell hybridomas. , 1991, Kidney international.

[243]  C. Ponticelli,et al.  The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. , 1991, Clinical nephrology.

[244]  B. Brenner,et al.  Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. , 1988, The Journal of clinical investigation.

[245]  E. Girardin,et al.  Immunopathological findings in idiopathic nephrosis: Clinical significance of glomerular “immune deposits” , 1988, Pediatric Nephrology.

[246]  G. Kollias,et al.  Ectopic expression of Thy-1 in the kidneys of transgenic mice induces functional and proliferative abnormalities , 1987, Cell.

[247]  M. Karnovsky,et al.  Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. , 1986, The American journal of pathology.

[248]  M. Fujishima,et al.  Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. , 1986, Kidney international.

[249]  R. Shalhoub Pathogenesis of lipoid nephrosis: a disorder of T-cell function. , 1974, Lancet.

[250]  A. Michael,et al.  Recurrence of idiopathic nephrotic syndrome after renal transplantation. , 1972, Lancet.

[251]  B. Ansell Corticosteroids , 2019, Reactions Weekly.

[252]  W. Tangheroni,et al.  [Proteinuria caused by transfusion of blood from nephrotic to non-nephrotic individuals]. , 1954, Minerva medica.

[253]  OUP accepted manuscript , 2022, Clinical Kidney Journal.

[254]  A. Jamin,et al.  Idiopathic nephrotic syndrome: the EBV hypothesis , 2017, Pediatric Research.

[255]  J. Kopp,et al.  Focal Segmental Glomerulosclerosis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[256]  R. Kew The Complement System , 2014 .

[257]  V. D’Agati,et al.  Focal segmental glomerulosclerosis. , 2011, The New England journal of medicine.

[258]  D. Gipson,et al.  Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[259]  P. Carmeliet,et al.  Modification of kidney barrier function by the urokinase receptor , 2008, Nature Medicine.

[260]  L. Sklar,et al.  Chemotactic Peptide/Complement Receptors , 2004 .

[261]  K. Tryggvason,et al.  The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. , 2001, Human molecular genetics.

[262]  A. Meyrier Treatment of primary focal segmental glomerulosclerosis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[263]  S. Korbet Clinical picture and outcome of primary focal segmental glomerulosclerosis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[264]  S. Zimmerman Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. , 1984, Clinical nephrology.

[265]  G. Remuzzi,et al.  Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[266]  The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. , 1981, The Journal of pediatrics.